

**ADOCIA**

innovative medicine  
for everyone, everywhere



## PRESS RELEASE

### Adocia: additional resources allocated to the liquidity agreement

**Lyon, France, February 12, 2017** -6:00 PM (CET) Adocia (Euronext Paris: FR0011184241 - ADOC), a clinical stage biopharmaceutical company focused on diabetes and other metabolic diseases with innovative formulations of approved proteins, today announced it has allocated an additional EUR 250,000 cash amount to the liquidity agreement entered into with Kepler Capital Markets SA.

As per the latest report dated December 29, 2017 the following resources were available under the liquidity agreement:

- 7,516 shares of Adocia and
- 26,247.01 euros in cash.

It is recalled that, according to the authorization granted by the last general shareholders' meeting dated June 27, 2017, the maximum purchase price per share (excluding charges and commissions) under this liquidity agreement amounts to EUR 50.

#### About Adocia

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins and peptides. Adocia's portfolio of injectable treatments for diabetes, featuring five clinical-stage products and three preclinical products, is among the largest and most differentiated of the industry. Adocia expanded its portfolio to develop treatments for obesity and short bowel syndrome.

The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application to address specific patient needs.

Adocia's clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of basal insulin glargine and rapid-acting insulin lispro (BioChaperone Combo). An aqueous formulation of human glucagon (BioChaperone Human Glucagon) successfully completed a Phase 1 trial. Adocia also develops a prandial combination of human insulin with amylin analog pramlintide (BioChaperone Pramlintide hIns), two combinations of insulin glargine with GLP-1 receptor agonists (BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide), a ready-to-use aqueous formulation of teduglutide (BioChaperone Teduglutide) and a ready-to-use combination of glucagon and exenatide (BioChaperone Glucagon Exenatide), all of which are in preclinical development.

*Adocia aims to deliver "Innovative medicine for everyone, everywhere."*

To learn more about Adocia, please visit us at [www.adocia.com](http://www.adocia.com)



For more information please contact:

|   |   |  |
|---|---|--|
| <b>Adocia</b><br>Gérard Soula<br>Chairman and CEO<br><a href="mailto:contactinvestisseurs@adocia.com">contactinvestisseurs@adocia.com</a><br>Ph. : +33 4 72 610 610 | <b>Adocia Press Relations Europe</b><br><b>MC Services AG</b><br>Raimund Gabriel<br><a href="mailto:adocia@mc-services.eu">adocia@mc-services.eu</a><br>Ph.: +49 89 210 228 0 | <b>Adocia Investor Relations USA</b><br><b>The Ruth Group</b><br>Tram Bui<br><a href="mailto:t.bui@theruthgroup.com">t.bui@theruthgroup.com</a><br>Ph. : +1 646 536 7035 |
|---|---|--|

#### Disclaimer

*This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the "Risk Factors" section of the Reference Document filed with the French Autorité des marchés financiers on April 11, 2017 (a copy of which is available on [www.adocia.com](http://www.adocia.com)) and to the development of economic conditions, financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Adocia to be materially different from such forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction.*